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Abstract 
We report a novel mitochondrial m.4414T > C variant in the mt-tRNA Met ( MT-TM ) gene in an adult patient with chronic progressive 
external ophthalmoplegia and myopathy whose muscle biopsy revealed focal cytochrome c oxidase (COX)-deficient and ragged red fibres. 
The m.4414T > C variant occurs at a strongly evolutionary conserved sequence position, disturbing a canonical base pair and disrupting the 
secondary and tertiary structure of the mt-tRNA Met . Definitive evidence of pathogenicity is provided by clear segregation of m.4414T > C 
mutant levels with COX deficiency in single muscle fibres. Interestingly, the variant is present in skeletal muscle at relatively low levels (30%) 
and undetectable in accessible, non-muscle tissues from the patient and her asymptomatic brother, emphasizing the continuing requirement for 
a diagnostic muscle biopsy as the preferred tissue for mtDNA genetic investigations of mt-tRNA variants leading to mitochondrial myopathy. 
© 2019 The Author(s). Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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(. Introduction 
Mitochondrial disorders are clinically and genetically 
eterogeneous and are caused by mutations in genes of
oth mitochondrial DNA (mtDNA) and nuclear DNA. Of the
tDNA point mutations causing mitochondrial disease, ∼50%
nvolve mitochondrial (mt-)tRNA genes [1–3] . Pathogenic
t-tRNA mutations typically display heteroplasmy, the
resence of both wild type and mutant mtDNA molecules
n a cell, and are often associated with the presence of
ocal ragged red fibres (RRFs) and cytochrome c oxidase∗ Corresponding author. 
E-mail address: debby.hellebrekers@mumc.nl (D.M.E.I. Hellebrekers). 
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960-8966/© 2019 The Author(s). Published by Elsevier B.V. This is an open ac
 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) COX)-deficient fibres in skeletal muscle, leading to a
ombined respiratory chain deficiency reflecting a disorder of
eneralised mitochondrial translation. Pathogenicity scoring 
ystems have been suggested for the accurate classification
f novel mt-tRNA variants, taking into account a number
f important factors including mtDNA heteroplasmy, tissue
istribution and segregation with a clear biochemical defect
4,5] . 
Here, we report a new m.4414T > C pathogenic variant in
he D-stem of the tRNA Met ( MT-TM ) gene in a 66-year-old
oman with mild mitochondrial disease manifesting as
hronic progressive external ophthalmoplegia (CPEO) and 
yopathy associated with focal COX-deficient and ragged-red
bres in skeletal muscle. 
cess article under the CC BY-NC-ND license. 
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G  2. Patient and methods 
2.1. Case report 
The patient is the second child of non-consanguineous
Dutch parents. She presented at the age of 66 years with
a variable, bilateral, ptosis which had been present for
approximately 3 years. Although she reported no evident
diplopia, reading a book was somewhat difficult since
the lines seemed to overlap each other. She had no
difficulties with her speech or swallowing. In retrospect, she
had exercise intolerance from childhood onwards, reflected
by difficulties in bicycling long distances, and avoiding
walking longer distances. Her medical history comprises a
retroperitoneal liposarcoma of the right groin, successfully
surgically removed, diabetes mellitus type 2, hypertension,
ocular hypertension for which she had laser iridotomy, and a
depression, for which she uses sertraline since 10 years. 
The patient’s brother is clinically unaffected. Her
two daughters report no symptoms, but refused further
examination. Both parents are deceased and were reported
to be in good health. 
On examination, at the age of 66, she had a bilateral
ptosis, which worsened by provocation, with varying diplopia
in all directions without clear opthalmoplegia. At that time,
there was no weakness in the extremities. Later on, she
developed an opthalmoparesis in all directions, bilateral
proximal weakness of the arms (shoulder abduction/shoulder
exorotation/elbow flexion MRC grade 4) and legs (hip
flexors/knee flexors MRC grade 4) and some distal weakness
of the feet (foot extensors MRC grade 4). Sensory
investigations were normal. 
Ancillary laboratory investigations showed normal thyroid
stimulating hormone (TSH) levels, blood lactate concentration
was elevated (3.1 mmol/l), as was fibroblast growth
factor-21 (FGF21; 917 pg/ml, normal reference range
0–200 pg/ml). Myasthenia gravis was ruled out: antibodies
against acetylcholine receptor and skeletal muscle were
negative, while repetitive nerve stimulation and single
fibre electromyography did not reveal any abnormalities.
Subcutaneously administered neostigmine did not lead to
improvement of the ptosis. Brain MRI to rule out brainstem
pathology was normal. Cardiac evaluation did not reveal
abnormalities. 
2.2. Muscle histology and histochemistry 
Standard histology (hematoxylin and eosin (H&E),
modified Gomori trichrome staining) and oxidative
enzyme histochemistry (cytochrome c oxidase (COX),
succinate dehydrogenase (SDH) and sequential COX/SDH
activities) were performed on 10- μm transversely
oriented frozen skeletal muscle sections, as described
previously [6] . Quadruple immunofluorescence analysis to
interrogate NDUFB8 (complex I) and COXI (complex IV)
immunoreactivities was performed as previously reported [7] ..3. Mitochondrial DNA (mtDNA) sequencing 
Total DNA was extracted from a skeletal muscle, hair,
rine and buccal samples by proteinase K digestion and
 DNeasy Blood and Tissue Kit (Qiagen); DNA isolation
rom blood was performed using a DSP DNA Midi kit
Qiagen). Large-scale mtDNA rearrangements were analyzed
y long-range PCR protocols [8] . Sequencing of the entire
itochondrial genome in muscle, including both detection and
uantification of variants, was performed by next generation
equencing using a MiSeq platform (Illumina) exactly as
eported [8] . Assessment of m.4414T > C heteroplasmy levels
n the blood, hair, buccal and urine DNA was also performed
y next generation sequencing. 
.4. Single muscle fibre segregation studies 
A novel m.4414T > C variant identified following mtDNA
equencing was further assessed in individual (COX-
eficient and COX-positive) skeletal muscle fibres isolated by
aser-capture microdissection by quantitative pyrosequencing
Pyromark Q24 platform, Qiagen) using mutation-specific
rimers (details available on request). The allele quantification
pplication of Pyromark’s proprietary Q24 software was used
o calculate heteroplasmy levels (level of test sensitivity > 3%
utant mtDNA) [9] . 
. Results 
.1. Histochemical and biochemical analyses 
The histopathological assessment of the patient’s skeletal
uscle biopsy showed numerous COX-deficient fibres
20–25% of the total biopsy). Sequential COX-SDH
istochemistry revealed that many of the COX-deficient
bres also showed subsarcolemmal mitochondrial aggregates,
orresponding to ragged-red fibres ( Fig. 1 (A)), indicating
n underlying mitochondrial aetiology. Quadruple
mmunofluorescence analysis in individual muscle
bres revealed the presence of fibres lacking NDUFB8
approximately 20% of all fibres) and COXI (24% of all
bres) proteins, confirming a multiple respiratory chain
bnormality ( Fig. 1 (B)). In addition, a clear correlation
etween the NDUFB8 and COXI expression levels in
ndividual muscle fibres was found, which is indicative for
 combined oxidative phosphorylation deficiency involving
oth complexes I and IV ( Fig. 1 (B)). 
.2. Molecular genetic analyses 
The patient’s muscle mtDNA was analysed for large-scale
eletions, as these are frequently associated with a CPEO
resentation [10] , but long-range PCR assays were all
ormal. Sequencing the entire mitochondrial genome in
uscle revealed a novel mt-tRNA Met ( MT-TM ) gene variant:
.4414T > C. This variant is absent from all 47,412 mtDNA
enBank sequences listed on MitoMAP [11] and has not been
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Fig. 1. Histological and histochemical analyses of the patient’s skeletal muscle biopsy. (A) Hematoxylin and eosin (H&E) staining ( i ), cytochrome c oxidase 
(COX) histochemistry ( ii ), succinate dehydrogenase (SDH) histochemistry ( iii ) and sequential COX-SDH histochemistry ( iv ). Scale bar = 100 μm. (B) Quadruple 
immunofluorescence analysis of NDUFB8 (complex I) and COXI (complex IV). Each dot represents the measurement from an individual muscle fibre, colour 
co-ordinated according to its mitochondrial mass (low = blue, normal = beige, high = orange, very high = red). Grey dashed lines represent SD limits for 
classification of the fibres. Lines next to x - and y -axis represent the levels of NDUFB8 and COXI: beige = normal ( > −3), light beige = intermediate positive 
( −3 to −4.5), light purple = intermediate negative ( −4.5 to −6), purple = deficient ( < −6). Bold dashed lines represent the mean expression level of normal 
fibres. 
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2  etected in > 3450 in-house mtDNA sequences collated in
aastricht and Newcastle upon Tyne. The single nucleotide
ubstitution was present at heteroplasmic levels ( ∼30%
utant load) in the patient’s skeletal muscle but was absent in
he patient’s blood, hair, urine and buccal samples, as well as
n blood, urine and buccal samples of her clinically-unaffected
rother, implying that it is a de novo sporadic mtDNA variant
 Fig. 2 (A)). 
Given it was present at relatively low levels in
keletal muscle, single muscle fibre segregation studies
ere performed to determine whether the m.4414T > C
ariant segregates with the observed respiratory chain defect.
uch an analysis revealed significantly higher levels of
he m.4414T > C variant in COX-deficient fibres (93.00 ±
.025%, n = 13) compared to COX-positive fibres (13.21
5.244%, n = 14, p < 0.0001 two-tailed Student’s t -test),
onfirming that the m.4414T > C variant is responsible for
he respiratory-deficient phenotype in the patient’s muscle
 Fig. 2 (B)). 
. Discussion 
We identified a novel pathogenic de novo sporadic
tDNA variant in the mitochondrial tRNA Met gene ( MT-TM ),
.4414T > C, in an adult patient with CPEO and myopathy
ssociated with focal COX-deficient and ragged-red fibres in
keletal muscle. A previously validated scoring system was used to
ssign a pathogenicity classification to this variant [4] . The
.4414T > C variant is not reported before and is absent from
vailable (online- and in-house-) databases. It is heteroplasmic
n muscle, the clinically affected tissue, and absent from
linically-unaffected tissues and the unaffected brother. The
.4414T > C variant is situated within the D-stem of the mt-
RNA Met molecule, affecting a highly evolutionarily conserved
ucleotide and disturbing a strong evolutionarily conserved
anonical Watson and Crick base pair [5] ( Fig. 2 (C) and
D)). In addition, the variant disrupts the tertiary structure
f the tRNA molecule [12] . The presence of a combined
xidative phosphorylation deficiency of complex I and IV,
s well as the focal COX-deficiency in the patient’s muscle,
re consistent with a pathogenic mt-tRNA variant. Finally,
ingle fibre studies reveal a clear segregation of m.4414T > C
utation load with the focal respiratory chain defect. Taken
ogether, the m.4414T > C variant scores 13 points with
vidence from a gold standard (single-fibre) investigation,
hereby fulfilling the accepted criteria for (definite)
athogenicity [4] . 
Pathogenic variants have been identified in each of the
2 human mt-tRNAs. The D -stem is a rather weak structure
f the tRNA and therefore prone to alterations causing
isturbance of secondary or tertiary interactions. So far,
isease causing D-stem variants are reported for 16 of the
2 mt-tRNA genes, and are associated with a wide range
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Fig. 2. Mitochondrial DNA studies revealing a pathogenic m.4414T > C variant. (A) Pedigree of the patient’s family. The proband is indicated with an arrow. 
Affected and unaffected status is indicated by black and white symbols, respectively. (B). Mutation load analysis in single COX-deficient and COX-positive 
muscle fibres. (C) Location of the m.4414T > C variant in the D -stem of the mt-tRNA Met . (D) Evolutionary conservation of the affected base. 
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T  of clinical presentations (Supplementary Table 1). Some of
these mt-tRNA D -stem cases have a relatively low (18–38%)
muscle mutation load and clearly show phenotypical overlap
with our patient, displaying relatively mild symptoms (mainly
CPEO, ptosis, myopathy) with an age of onset at 26–66 years
[13–17] . As compared to other pathogenic variants in the
tRNA Met gene (summarized in [18] ) our patient has a much
lower muscle heteroplasmy level, probably responsible for the
milder phenotype and later onset of disease than the other
reported MT-TM patients. 
The heteroplasmy level of the m.4414T > C varaint in
skeletal muscle of our patient is relatively low, as documented
for many mt-tRNA variants causing a CPEO phenotype.
It is tempting to speculate that mutation levels might be
higher in clinically-affected extraocular muscle tissue as
reported by others, although we were unable to test this
[19] . Furthermore, CPEO-associated mt-tRNA variants often
occur sporadically and are restricted to muscle, which
has implications for diagnosis, highlighting the requirement
for muscle biopsy to perform mtDNA diagnostic testing,
despite the high sensitivity of the current NGS-based mtDNA
screening techniques [20,21] . . Conclusion 
In summary, we report a novel pathogenic de novo sporadic
tDNA variant in the mitochondrial tRNA Met gene ( MT-TM ),
.4414T > C, in an adult patient with CPEO and myopathy
ssociated with focal COX-deficient and ragged-red fibres
n skeletal muscle. The relatively low m.4414T > C mutation
evels (30%) in skeletal muscle and absence in non-muscle
issues emphasize that a diagnostic muscle biopsy remains
he preferred tissue for mtDNA investigation in patients with
 myopathic phenotype. 
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